Literature DB >> 23444764

Conservative management of massive hematoperitoneum caused by ovulation in a patient with severe form of von Willebrand disease--a case report.

M Terzic1, I Likic, I Pilic, J Bila, N Knezevic.   

Abstract

Von Willebrand disease (VWD) is the most common inherited bleeding condition that involves extended or excessive bleeding, caused by the deficiency or defect of von Willebrand factor (VWF). Hematoperitoneum as a complication of gynecologic diseases represents acute condition which is usually caused by the hemorrhagic corpus luteum or a rupture of either ectopic pregnancy or a hemorrhagic ovarian cyst. The authors present a unique case of conservatively managed massive hematoperitoneum caused by ovulation in a patient with severe form of von Willebrand disease who had right adnexectomy due to hemorrhagic corpus luteum four months prior. This conservative management by blood product and factor concentrate support could be a method of choice in selected hemodynamically stable patients. Furthermore, recurrent bleeding episodes following ovulation could be prevented by suppression of ovulation using oral contraceptive pills.

Entities:  

Mesh:

Year:  2012        PMID: 23444764

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  3 in total

1.  Leukaemia-associated Rho guanine nucleotide exchange factor (LARG) plays an agonist specific role in platelet function through RhoA activation.

Authors:  Siying Zou; Alexandra M Teixeira; Mingzhu Yin; Yaozu Xiang; Juliana Xavier-Ferrucio; Ping-Xia Zhang; John Hwa; Wang Min; Diane S Krause
Journal:  Thromb Haemost       Date:  2016-06-23       Impact factor: 5.249

Review 2.  Hemorrhagic corpus luteum: Clinical management update.

Authors:  Mykhailo V Medvediev; Antonio Malvasi; Sarah Gustapane; Andrea Tinelli
Journal:  Turk J Obstet Gynecol       Date:  2020-12-10

Review 3.  Corpus luteum hemorrhage with acquired hemophilia A: a case report and literature review.

Authors:  Xiaofei Xie; Shaoru Jiang
Journal:  BMC Womens Health       Date:  2022-10-11       Impact factor: 2.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.